Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3585-3599
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3585
Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors
De-Gang Li, Jia-Peng Jiang, Fan-Ye Chen, Wei Wu, Jun Fu, Gong-He Wang, Yu-Bo Li
De-Gang Li, Jia-Peng Jiang, Fan-Ye Chen, Wei Wu, Jun Fu, Gong-He Wang, Yu-Bo Li, Department of Gastrointestinal and Anorectal Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi Zhuang Autonomous Region, China
Author contributions: Li DG and Li YB designed the study; Jiang JP, Chen FY and Wu W collected the data; Fu J, Wang GH and Li YB analyzed the data; Li DG wrote the manuscript. All authors reviewed and approved the final manuscript.
Institutional animal care and use committee statement: All animal experiments were approved by the Animal Ethics Committee of Beijing Viewsolid Biotechnology Co. LTD (VS2126A00170).
Conflict-of-interest statement: All authors have nothing to disclose.
Data sharing statement: The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary materials.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Bo Li, MM, Associate Chief Physician, Department of Gastrointestinal and Anorectal Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Nanning 530023, Guangxi Zhuang Autonomous Region, China. gzyzyyfygc@126.com
Received: January 5, 2024
Revised: June 6, 2024
Accepted: June 25, 2024
Published online: August 15, 2024
Processing time: 215 Days and 21.7 Hours
Core Tip

Core Tip: Our study found that insulin-like growth factor 2 (IGF2) regulated metastasis and imatinib resistance in gastrointestinal stromal tumors (GISTs). IGF2 interacted with IGF1R to regulate glycolysis. Our results confirm that IGF2 targeting of IGF1R signaling inhibited metastasis and improved imatinib chemosensitivity by driving glycolysis in GISTs and indicated that IGF2 might be used to reverse imatinib resistance in GIST patients.